Virus injection halts pancreatic cancer in three patients
Archived — this story has rotated out of today’s deck. It is kept here in full.
The gist
A modified virus halted tumour growth in three pancreatic cancer patients at one-tenth of the target dose.
The patients were not cured, and larger trials with control groups are still needed.
Background
Masato Yamamoto, a researcher at the University of Minnesota, led development of the viral treatment. Pancreatic cancer is described as the deadliest type of cancer: symptoms appear late, when the cancer has often spread and cannot be removed surgically, and people usually live only around three to six months after diagnosis. Pancreatic tumours have tough, fibrous exteriors that block chemotherapy drugs, and immunotherapies are ineffective because the tumours can hide from the immune system. The results were presented at the annual meeting of the American Society of Gene and Cell Therapy in Boston, Massachusetts.
How it unfolded
- recentlyThe first patient, whose pancreatic tumour was 7 centimetres across, was treated a year ago; the other two were treated since then. At treatment their tumours had not spread beyond the pancreas and have not grown further.
- earlier this monthResults were presented at the annual meeting of the American Society of Gene and Cell Therapy in Boston, Massachusetts.
- Nov 18, 2026A Victoria Health Clinic Facebook post described Spanish researchers combining a genetically modified adenovirus with chemotherapy against pancreatic cancer.
- Nov 19, 2026Physician Partha Nandi posted that three patients experienced stable disease after the experimental virus treatment, noting they were not cured and larger trials are needed. A Hacker News item on the story was also posted.
Key terms
- control groups
- In comparative experiments, the group that receives a standard treatment, a placebo, or no treatment at all.
- chemotherapy
- A cancer treatment that uses one or more anti-cancer drugs, given to cure, prolong life, or relieve symptoms.
- phase III testing
- A late stage of clinical research testing a treatment's effectiveness in many participants after early safety testing.
Source: Wikipedia
Who’s saying what
- Researcher
- Masato Yamamoto said only one-tenth of the eventual dose was injected, so the efficacy is better than he expected, especially for pancreatic cancer, and that all three patients are still alive with clinically stable disease.
- Caution
- Pancreatic surgeon Kai Brown called it an interesting early signal but said the history of oncology is littered with promising early signals that vanished by the time rigorous phase III testing was done, and the trial has no control group.
- Expert
- Partha Nandi, MD, said the findings are preliminary, the patients were not cured, and larger clinical trials are needed.
- Public
- Commenters on the coverage noted the headline leaves out context, that it was a tiny initial safety trial of three patients where tumours temporarily stopped growing rather than a cure.
Still unverified
The results are preliminary and further evaluation in larger trials is needed; the trial so far has had no control group, so it is hard to know whether the virus works better than other treatments or none at all.